Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 1,576.8% | 5,800% | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | 98.9% | 48% | -2,638.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -74.9% | -920% | -70,002.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -83.8% | -860% | -74,044.1% |
| EPS Diluted | -0.4 | -0.39 | -0.25 | -0.38 |
| % Growth | -2.6% | -56% | 34.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |